INTRODUCTION
Lysosomal proteins are synthesized as soluble or membrane-integrated glycoproteins in the rough endoplasmic reticulum (ER). In mammalian cells, mannose-6-phosphate receptors (MPRs) mediate the transport of the majority of lysosomal enzymes to lysosomes. Mannose-6-phosphate (Man-6-P) terminal residues are recognized in the trans-Golgi network (TGN) by two MPRs which mediate the sorting of lysosomal enzymes from the secretory pathway and deliver them to a prelysosomal compartment from where the receptors return to the TGN and the ligands are forwarded to dense lysosomes (reviewed in Kornfeld, 1992; Kornfeld and Mellman, 1989; Ludwig et al., 1995) . It has also been postulated, however, that alternative MPR-independent mechanisms must exist for the transport and sorting of a subset of lysosomal enzymes. This conclusion has been based in part on work done in I-cell disease (ICD) patient fibroblasts, in which the lack of addition of Man-6-P moieties to lysosomal enzymes results in the strongly increased secretion of many, but not all, of these enzymes (Ginsel and Fransen, 1991; Glickman and Kornfeld, 1993; Neufeld, 1991) . Additional support suggesting that some lysosomal enzymes do not rely on the MPRs has also come from studies done in MPR-deficient mice (Dittmer et al., 1999; Kasper et al., 1996; Ludwig et al., 1994) .
The lysosomal hydrolase b-glucocerebrosidase (bGC) is an example of one such enzyme that is unaffected by perturbations to the MPR-dependent pathway. In fibroblasts of ICD patients it has been shown to be intracellularly retained, suggesting that signals other than Man-6-P are responsible for targeting this enzyme (Aerts et al., 1988; van Dongen et al., 1985) . Mutations within the gene coding for human bGC are the cause of the most common lysosomal storage disorder, Gaucher disease, in which the defective enzyme leads to an accumulation of glucosylceramide (GlcCer) (Beutler, 1991 (Beutler, , 2006 . Although the clinical course of this disease has been well described and an efficient treatment option, enzyme replacement therapy, is available, little is known about how GlcCer accumulation in lysosomes leads to cellular pathology. Also, the mechanism by which bGC is targeted from its site of synthesis in the ER to lysosomes is not well understood.
In the present study, we identified the lysosomal integral membrane protein type 2 (LIMP-2) as a specific binding partner for bGC. LIMP-2 is a heavily N-glycosylated 478 residue type III transmembrane protein (Fujita et al., 1991) comprised of a $400 amino acid lumenal domain, two transmembrane domains, and a cytoplasmic domain of 20 amino acids. Based on homology, LIMP-2 has been defined as a member of the CD36 family of scavenger receptor proteins (Febbraio et al., 2001; Krieger, 2001) . We recently showed that overexpression of LIMP-2 caused an enlargement of early endosomes and late endosomes/lysosomes and an impairment of endocytotic membrane traffic out of the enlarged compartments (Kuronita et al., 2002 (Kuronita et al., , 2005 . A deficiency of LIMP-2 in mice caused ureteric pelvic junction obstruction, deafness, and peripheral neuropathy (Gamp et al., 2003) associated with impaired vesicular trafficking and distribution of apically expressed proteins (Knipper et al., 2006) .
We present here in vitro and in vivo evidence that LIMP-2 acts as a receptor to bind bGC and that the bGC/LIMP-2 complex is transported to the lysosomal compartment in an MPR-independent pathway.
RESULTS

Isolation and Identification of LIMP-2 as a b-Glucocerebrosidase-Interacting Protein
The intracellular trafficking and enzymatic activity of bGC, unlike that of most lysosomal hydrolases, is unaffected in mouse embryonic fibroblasts doubly deficient for both MPRs (see Figure S1 in Supplemental Data available with this article online). In an attempt to identify proteins involved in the intracellular trafficking of bGC, we employed an affinity-chromatography approach. A total detergent-soluble extract of murine liver was passed over recombinant bGC affinity resin and following extensive washing of the resin-bound proteins were eluted using pH 4.7 acetate buffer, collected, and then analyzed by SDS-PAGE and silver staining ( Figure 1A) . A sample of the same extract was also passed over a control resin to which an equimolar amount of BSA had been coupled to monitor nonspecific background binding of proteins to the resin. Comparison of the eluates from the two columns revealed that a polypeptide with an apparent mass of 75 kDa was present in the fractions eluted from the bGC resin but not the control resin ( Figure 1A ). To further evaluate the specificity of this binding candidate for bGC, a series of small-scale affinity binding reactions was run in the presence of excess soluble bGC or BSA. Competition with a 4-fold molar excess of soluble bGC prevented binding of the 75 kDa polypeptide to the bGC resin ( Figure 1B ). Molar excess of BSA had no effect on 75 kDa polypeptide binding. These results further substantiated that the 75 kDa polypeptide was binding specifically to bGC. To determine the identity of this protein, fractions from a large-scale bGC-affinity column enriched in the 75 kDa polypeptide were resolved by SDS-PAGE and the band of interest was excised, in-gel digested with trypsin, and sequenced using nano-LC-MS/MS. Based on the amino acid sequences obtained, the polypeptide was identified as the lysosomal integral membrane protein LIMP-2. PNGase-F treatment to remove N-linked carbohydrates resulted in a mobility shift of this polypeptide from 75 kDa to 54 kDa ( Figure 1C) , which is the molecular mass calculated for deglycosylated LIMP-2.
The Lumenal Domain of LIMP-2 Is Required for Association with b-Glucocerebrosidase bGC resides in lysosomes as a protein associated with the lumenal membrane (Rijnboutt et al., 1991) . Topologically, the lumenal portion of the LIMP-2 polypeptide is also expected to be in close proximity to this membrane (Okazaki et al., 1992) . Therefore, we investigated whether this region in LIMP-2 might be responsible for the association with bGC. Recombinant fusion-tagged LIMP-2 lumenal domain protein (L2LD) encompassing residues 27-432 was expressed as a soluble protein, purified, and then used in an in vitro pull-down assay with bGC ( Figure 1D ). bGC bound specifically to L2LD, indicating that the lumenal domain of LIMP-2 is sufficient for the interaction and that the binding between these two proteins is direct. We also investigated whether the corresponding lumenal region of CD36 (CD36LD) might have the capacity to bind bGC in this assay, as CD36 and LIMP-2 share $34% overall sequence identity, the majority of which is found across the lumenal domain ( Figure 1D ). No binding of CD36LD was detected, indicating that the interaction of bGC with LIMP-2 likely depends on features unique to the LIMP-2 lumenal domain. When a similar in vitro pull-down assay was performed using recombinant fusion-tagged LIMP-2 cytoplasmic domain protein or the isolated N-or C-terminal halves of the lumenal domain (residues 27-155 or 155-432), no binding of bGC was detected (data not shown). These data support a scenario in which domains of LIMP-2 and bGC could interact within the lumen of some or all of the secretory compartments in which they coexist.
Our efforts to isolate and identify LIMP-2 from tissue extracts revealed that full-length endogenous LIMP-2 could be released effectively from bGC affinity resin by elution with buffers at lysosomal pH. bGC passes through intracellular compartments of varying pH en route from its point of synthesis in the ER to its final destination in lysosomes. To determine compartments in which the association or dissociation of LIMP-2 and bGC may occur, the ability of bGC affinity resin to bind L2LD over a range of pH values was tested via small-scale in vitro binding reactions ( Figure 1E ). Binding of L2LD to the bGC resin was favored at neutral pH and attenuated as the pH approached that typical of the lysosomal lumen. This suggested that the most probable points of bGC and LIMP-2 association are prelysosomal, possibly beginning in compartments as early as the ER or Golgi apparatus.
Effects of LIMP-2 Deficiency on b-Glucocerebrosidase Activity, Expression, and Localization Our in vitro binding data support a situation in which bGC and LIMP-2 interact directly within intracellular trafficking compartments of cells. To further test this hypothesis, we explored the effects of LIMP-2 deficiency in the LIMP-2 knockout (KO) mouse to determine whether there might be bGC-specific consequences. We evaluated bGC activity levels in total tissue homogenates from wild-type and LIMP-2 KO mice ( Figure 2A ). The activity of another lysosomal hydrolase, a-galactosidase, which does not bind the lumenal domain of LIMP-2 in in vitro assays (data not shown), was also assayed for comparison ( Figure 2B ). bGC activity was significantly decreased in all of the KO tissue samples relative to wild-type; this difference was most notable in liver, where the average decrease was greater than 75% ( Figure 2A ). In contrast, such a reduction was not seen when the activity of agalactosidase was measured in the same samples. Immunoblotting revealed a very significant and consistent decrease in the levels of bGC protein in each of four KO liver samples compared to wild-type ( Figure 2C , right panel). Anti-bGC immunoblots of kidney homogenates prepared from these same animals yielded identical results ( Figure 2C , left panel). To determine whether the reduced expression level was because of changes at the (E) Effect of pH on the association of bGC and the lumenal domain of LIMP-2. Binding reactions using bGC affinity resin and soluble L2-LD were set up in a series of buffers ranging from pH 4.5 to 8.5. Following incubation, the resin was washed in buffer of the same pH as used in each respective binding reaction, and then any bound L2-LD protein was eluted in Laemmli buffer and analyzed by SDS-PAGE and Coomassie staining. The arrowhead indicates the migration of L2-LD. transcription level, we performed a northern blot analysis of RNA derived from liver and kidney of wild-type and LIMP-2 KO mice. The bGC transcript levels were not significantly different between the two genotypes ( Figure 2D ), suggesting that the decrease in bGC protein expression was a result of posttranscriptional events.
The differences in bGC enzyme activity detected between LIMP-2 wild-type and KO tissues are almost certainly a reflection of the drop in total bGC protein levels, a conclusion that is further substantiated by immunohistochemical staining ( Figure 2E ). Spleen (not shown) and liver sections of WT and LIMP-2 KO mice were stained for LIMP-2 (Figures 2Ea and 2Eb ), bGC (Figures 2Ec and 2Ed), and LAMP-1 (Figures 2Ee and 2Ef ). In wild-type tissues as exemplified by liver, LIMP-2 and bGC colocalized with LAMP-1 in lysosomes, whereas in LIMP-2 KO tissue, neither LIMP-2 nor bGC staining was visible. However, the levels and subcellular distribution of LAMP-1 in KO tissue appeared normal, indicating that the integrity of the lysosomal compartment is maintained in LIMP-2-deficient tissue. In a wide spectrum of tissues, a tight correlation between the relative levels of bGC and LIMP-2 protein was detected such that in samples in which LIMP-2 was absent, bGC was deficient, but in samples in which LIMP-2 was present, bGC was readily detectable ( Figure S2 ).
Reduction of lysosomal bGC levels has been found to correlate with an increase in the bGC substrate GlcCer in Gaucher disease (Brady et al., 1965; Nilsson et al., 1985; Nilsson and Svennerholm, 1982) . Analysis of GlcCer levels in tissues isolated from wild-type and LIMP-2 KO mice revealed an almost 2-fold increase of GlcCer in the liver and lung from LIMP-2-deficient animals compared to normal (Table 1) .
LIMP-2-Deficient Lysosomes Are Depleted of b-Glucocerebrosidase
To more precisely define the molecular events leading to the reduction in bGC activity levels in LIMP-2 KO tissues, we examined the status of bGC in mouse embryonic fibroblast (MEF) cells derived from wild-type and LIMP-2 KO embryos. Both the activity ( Figure 2F ) and the level of bGC protein ( Figure 2G ) were dramatically reduced in the extracts from LIMP-2 KO MEF cells. Immunostaining for bGC in MEFs revealed that in WT cells, bGC localized in LAMP-2-positive lysosomal compartments, whereas in LIMP-2 KO MEF cells ( Figure 2H ) or HeLa cells with an siRNA-mediated downregulation of LIMP-2 ( Figure S3 ), almost no lysosomal bGC could be detected. Although in a minority of LIMP-2 KO MEF cells a very weak lysosomal bGC staining was still detectable (not shown), in the majority of these cells it appeared that most if not all the bGC had been secreted. Overexpression of bGC in LIMP-2 KO cells revealed that bGC is retained in the ER and unable to be delivered to the lysosomal compartment ( Figure S4 ).
Given the dramatic effects of LIMP-2 deficiency on the status of bGC in cells, we investigated whether LIMP-2 was directly required for the correct lysosomal localization of bGC. For this we transfected myc-tagged murine LIMP-2 into LIMP-2 KO MEF cells and assessed whether LIMP-2 expression could rescue the mislocalization of bGC. Transfected cells could easily be identified by staining with antibodies against the lumenal domain of LIMP-2 (not shown) or against the myc epitope ( Figures 3A-3C ). In 95% of LIMP-2-transfected cells, but not in LIMP-2 KO cells transfected with another lysosomal membrane protein (LAMP-2; data not shown), the bGC expression level could be rescued to wild-type levels (see Figure 2Ha ) and bGC colocalized with LIMP-2 in lysosomal compartments ( Figure 3C ). The juxta-membrane localization of both LIMP-2 and bGC is demonstrated by their ring-like staining pattern in the intracellular vesicles. A triple staining with LIMP-2, bGC, and LAMP-2 ( Figures 3D-3G ) confirmed the correct lysosomal sorting of bGC after LIMP-2 re-expression. Immunoblot analysis after transient transfection of LIMP-2 in KO MEF cells confirmed the microscopical results. Expression of LIMP-2 led to an increase in the general bGC level and in the mature, most likely lysosomal, form of bGC ( Figure 3H ).
The requirement of LIMP-2 for the lysosomal localization of bGC was also supported by an additional experiment in COS cells in which LIMP-2 expression enabled the efficient delivery of bGC to the lysosomal compartment, but the fusion of LIMP-2 to a strong ER retention motif (Zerangue et al., 2000) prevented the transport of bGC out of the ER (Figures 4A-4F ). Coimmunoprecipitation confirmed the association of LIMP-2 and bGC as well as the association of the LIMP-2 ER retention mutant with bGC ( Figures 4G and S5A ), again suggesting that binding of these proteins can occur in compartments as early as the endoplasmic reticulum. We also tested the expression in COS cells of a truncated version of LIMP-2 (LIMP-2 [ld]) in which the lumenal domain was fused to the bGC signal peptide to target it to the extracellular space. LIMP-2 (ld) was found to be secreted. Coexpression of this LIMP-2 construct with bGC led to a dramatic increase in the amount of bGC secreted compared to that seen upon the expression of bGC on its own (Figure S5B) . Such an increase was not seen when wild-type LIMP-2 was coexpressed with bGC. These data provided additional evidence for the association of these proteins.
A Coiled-Coil Motif within the Lumenal Domain of LIMP-2 Is Needed for b-Glucocerebrosidase Binding The isolated halves of the LIMP-2 lumenal domain (residues 27-155 and 155-432) do not bind bGC (data not shown). This suggested to us that a region around amino acid residue 155 might be required for the bGC-LIMP-2 association. Exploring this hypothesis, we discovered a conserved coiled-coil domain of LIMP-2 from amino acid residues 150-167 ( Figures 5A and 5B ). When we disrupted the putative coil-coiled domain by deleting this region (LIMP-2Dcc) or by replacing a leucine by a proline at amino acid position 160 (LIMP-2-L160P), the resultant mutants failed to rescue lysosomal bGC expression in LIMP-2-deficient MEF cells despite the fact that both mutants were, like wild-type LIMP-2 ( Figure 5A ), delivered normally to the lysosomal compartment ( Figures 5C and  5D ). Coimmunoprecipitation analysis indicated that the physical interaction between endogenous bGC and LIMP-2 was lost in the case of both mutants ( Figure 5E ). In vitro pull-down experiments using purified recombinant proteins further confirmed the lack of bGC binding to the LIMP-2-L160P mutant (data not shown). Taken together, these results strongly suggest that the LIMP-2 region from residues 150-167 is crucially involved in the binding of LIMP-2 to bGC.
LIMP-2 Expression Leads to Lysosomal Localization of a Clinical Glucocerebrosidase Mutant Normally Retained in the Endoplasmic Reticulum
To analyze whether any of the more common clinical mutations within bGC affected binding to LIMP-2, we expressed bGC N370S, G202R, and L444P and analyzed the interaction of LIMP-2 and these mutant proteins in our in vitro binding assay. None of these mutations in bGC abrogated the binding to LIMP-2 ( Figure S6) . Interestingly, however, we observed that LIMP-2 expression led to transport of bGC L444P, a known ER retention mutant (Schmitz et al., 2005) , to the lysosomal compartment ( Figure 5F ), suggesting that LIMP-2 can bind bGC within the endoplasmic reticulum and that an increase in LIMP-2 expression may be sufficient to overcome the ER retention of specific Gaucher mutants. Interestingly, the ER localization of another clinical bGC mutant, P415R, was not altered after overexpression of LIMP-2 ( Figure S6B ), suggesting a direct or indirect effect of this mutation on binding to LIMP-2.
b-Glucocerebrosidase Is Mistargeted In Vitro and In Vivo Because MPR-deficient mice and I-cell disease patients exhibit increased levels of several lysosomal enzymes in their serum, we examined whether an analogous observation might be made for bGC in the serum of LIMP-2 KO mice. Sera from wild-type and LIMP-2 KO mice were collected and total normalized protein samples were analyzed for bGC levels by immunoblot. Whereas no bGC was found in the sera of wild-type mice, a significant level of bGC was observed in the serum from LIMP-2 KO mice ( Figure 6A ). This observation corresponded with an approximately 11-fold increase in bGC activity in the sera from LIMP-2 KO animals ( Figure 6B ) compared to that in wild-type mice. These results provide in vivo evidence that a lack of LIMP-2 leads to the mistargeting of bGC to the extracellular space. To investigate this mistargeting in isolated LIMP-2 KO cells, we incubated wild-type and LIMP-2 KO macrophage preparations in serum-free medium for 24 hr and analyzed bGC levels in cell extracts and culture supernatants ( Figure 6C ). In agreement with our in vivo observations, we observed a significant increase in bGC protein levels in the culture supernatants of LIMP-2 KO macrophages. In wild-type cells, only about 5%-7% of the total bGC was found to be secreted. In LIMP-2 KO macrophages, between 46% and 47% of total bGC was found in the medium ( Figure 6D ). Similar findings were made in MEF cells, which also showed a large increase in the secretion of bGC in the absence of LIMP-2 ( Figure S7 ). Using PNGase-F digestion, we observed that the molecular weight of intracellular bGC was reduced from 54 kDa to about 50 kDa in both wild-type and LIMP-2 KO MEF cells ( Figure 6E ). EndoH treatment, which does not affect glycosylated proteins that have passed the Golgi apparatus, revealed that in wild-type MEF cells more than 90% of the bGC was EndoH resistant, indicating that it has left the ER. In contrast, the same EndoH treatment in LIMP-2 KO MEF cells, despite a lower overall bGC protein level, led to a complete digestion of the bGC carbohydrates, suggesting that residual bGC in the absence of LIMP-2 is trapped in the ER.
Pulse-chase experiments in HeLa cells depleted of LIMP-2 using siRNA allowed us to examine the fate of bGC over time under conditions of LIMP-2 deficiency ( Figure 6F ). Whereas in mock treated cells bGC starts to become EndoH resistant after 30-60 min indicating it has left the ER, LIMP-2 siRNA treatment leads to ER LAMP-1 staining shows lysosomal structures in wild-type (e) and LIMP-2 KO liver (f). Insets show magnification of merged images of GC and LAMP-1 staining demonstrating lysosomal localization of GC in wild-type but not in LIMP-2 KO hepatocytes. The scale bars represent 50 mm. Liver and lung tissue samples (n = 4 for each) were analyzed for GlcCer substrate levels utilizing a mass spectrometrybased assay (see Experimental Procedures).
retention until 120 min of chase and a dramatic reduction in intracellular bGC between 120 and 480 min (Figures 6Fa  and 6Fc ). This drop correlated with the missorting of bGC into the cell culture supernatant between 120 and 480 min (Figures 6Fb and 6Fc) . In contrast, the processing and secretion of cathepsin D was not affected by the downregulation of LIMP-2 (data not shown). Proteasomal degradation of bGC in the absence or downregulation of LIMP-2 was excluded, as inhibition of the proteasome did not alter bGC protein levels ( Figure S8 ). Taken together, these experiments show that LIMP-2 is required for the intracellular retention of bGC and that a failure to bind LIMP-2 leads to mistargeting and a marked increase in the secretion of bGC.
DISCUSSION
In the present study, we have identified an unexpected role for LIMP-2 as a sorting receptor required for the delivery of b-glucocerebrosidase to lysosomes. The Man-6-Preceptor pathway has been very well characterized as a major route for the sorting of lysosomal enzymes; however, the mechanism for the intracellular targeting of bGC to lysosomes has been unclear until now.
Our findings that bGC associates with LIMP-2, that these proteins colocalize in intracellular vesicular compartments, and that the activity, levels, and localization of bGC exhibit a dramatic correlation with the presence or absence of LIMP-2 reveal that bGC independence of M6P-based sorting mechanisms is almost certainly a consequence of its routing via LIMP-2 through the lysosomal membrane protein delivery pathway. Lysosomal membrane proteins, in contrast to soluble M6PR binding lysosomal proteins, are directed from the Golgi to lysosomes after incorporation into clathrin-coated vesicles by virtue of the interaction of distinct targeting motifs in their cytoplasmic tails with multimeric adaptor proteins; in the case of LIMP-2, an association with AP-3 (Honing et al., 1998) and AP-1 (Fujita et al., 1999) has been suggested. The evidence that the association of bGC and LIMP-2 is sensitive to changes in the range of pH values found within the intracellular compartments through which these proteins pass is also consistent with a model for LIMP-2-based trafficking (Figure 7) . Preliminary crosslinking experiments (data not shown) with LIMP-2 and bGC coexpressed in COS cells suggest that the protein-protein complex is about 250 kDa in size, which would fit with a 2:2 bGC:LIMP-2 stoichiometry (Figure 7, insert) . These data support a scenario in which LIMP-2 and bGC would associate in the ER at more neutral pH and subsequently dissociate in the lysosome at more acidic pH. Such an early association is supported by our coimmunoprecipitation experiments, in particular after expression of a LIMP-2 ER retention mutant. Interestingly, we also observed that a clinical mutant of bGC, L444P, which is usually retained in the ER, can be shifted to the lysosomal compartment after coexpression of LIMP-2. These data not only suggest that an increase in LIMP-2 levels may be of some therapeutic interest for selected bGC mutations but also support our other data demonstrating that interaction can occur in the endoplasmic reticulum. When the fate of newly synthesized bGC was monitored in the absence of LIMP-2, we observed that bGC release from the ER was retarded before bGC was missorted and secreted, suggesting that LIMP-2 binding to bGC is needed for efficient ER exit toward the lysosomal compartment. bGC secretion in the absence of LIMP-2 is also substantiated by our experiments with proteasomal inhibitors, which did not affect the rapid intracellular loss of bGC ( Figure S8 ). In contrast to lysosomal delivery of M6PR-targeted proteins or proteins such as the major histocompatibility complex II through the binding of the invariant chain (Trombetta and Mellman, 2005) , where diversion from the constitutive secretory pathway occurs after leaving the trans-Golgi network (Kornfeld, 1992) (Figure 7) , it appears that lysosomal bGC trafficking requires LIMP-2 binding already taking place in the ER. Our observation that modulation of carbohydrates has no effect on the association of both proteins (data not shown) also substantiates association in the ER. It is also conceivable that the early association of both proteins generates a signal for sorting within the TGN.
bGC associates with membranes in a carbohydrateindependent manner (Aerts et al., 1988; Leonova and Grabowski, 2000) , and this persists from the ER through lysosomes (Rijnboutt et al., 1991) . Interestingly, we found that overexpression of LIMP-2 in COS cells significantly enhanced the membrane association of coexpressed bGC compared to the expression of bGC on its own ( Figure S9 ), further emphasizing the importance of the LIMP-2/bGC interaction in vesicular compartments. Our data also revealed that the binding of LIMP-2 and bGC appeared to be stable during transport through the Golgi apparatus, as expression of a secreted LIMP-2 mutant also led to a significant missorting and consequent increase of secreted bGC. Moreover, it seems unlikely that a defect in endocytosis of bGC underlies the increased extracellular levels of the enzyme, as uptake of iodinated bGC in LIMP-2 KO cells is unimpaired (data not shown). Disruption of the coiled-coil probability is shown in the insets. Coiled-coil probabilities within the lumenal domain of (A) LIMP-2wt, (C) LIMP-2-Dcc, and (D) LIMP-2-L160P were determined with the program Coils (version 2.2). The x axes represent the amino acid position, whereas the y axes illustrate the coiled-coil probability. Single labeling is shown in the black and white images. It is still unclear whether LIMP-2 might, similarly to the M6PR, also recycle back from endosomes to the Golgi apparatus, and we cannot completely rule out the possibility that other lysosomal proteins might also bind to LIMP-2 at this point. The results from our affinity-chromatography experiments with mouse liver extract and the lack of LIMP-2 association with a-galactosidase and a-glucosidase (data not shown), however, highlight a rather specific nature for the LIMP-2/bGC interaction. LIMP-2 is homologous to CD36 and defines it as a member of the CD36-scavenger receptor-like protein family (Vega et al., 1991) . Despite the fact that LIMP-2 and CD36 share $34% sequence identity over their lumenal domains, we found that bGC did not bind to this region of CD36 under conditions in which it bound the corresponding region in LIMP-2. Thrombospondin 1 (TSP-1), however, has been demonstrated to bind both CD36 and LIMP-2 (Asch et al., 1987; Crombie and Silverstein, 1998) . The differing ability of these two family members to bind bGC suggests that, as a ligand, bGC has an apparently higher level of specificity for LIMP-2 than does TSP-1. Because LIMP-2 is predominantly localized on intracellular membranebound compartments and exhibits only low levels of cellsurface expression (Okazaki et al., 1992; Suarez-Quian, 1987) , it is possible that the interaction between LIMP-2 and TSP-1 does not predominate in the physiological setting, particularly given that TSP-1 is found in the matricellular environment. It may be that there are two subtypes to the CD36 family: proteins such as LIMP-2 which function intracellularly, and others like CD36 that preferentially act at the plasma membrane.
Our binding studies indicate that bGC interacts with a coiled-coil domain in the lumenal domain of LIMP-2. The disruption of the coiled-coil domain abolished interaction with bGC yet allowed normal expression and lysosomal transport of these LIMP-2 mutants. Coiled-coil domains have been shown to be involved in protein-protein interaction (Lupas et al., 1991) , and our experiments revealed a critical role of this domain in LIMP-2 for bGC binding. A more detailed structural analysis, however, will be necessary to completely resolve the nature of the binding of both proteins.
A large variety of mutations that occur in the gene encoding bGC result in the accumulation of its substrate glucosylceramide (GlcCer) and consequently lead to Gaucher disease in humans (for a review, see Sidransky, 2004) . Manifestation of this disease is typically a result of a deficiency in enzyme activity, inappropriate bGC localization, decreased bGC stability, or a combination of these factors (Beutler and Kuhl, 1986; Liou et al., 2006; Schmitz et al., 2005) . We found that the levels of GlcCer substrate were elevated in LIMP-2-deficient liver and lung but apparently unaffected in other tissues, namely kidney, spleen, and brain (data not shown). Such tissuespecific differences could result from differences in substrate availability or utilization in each tissue; alternatively, they could be because of varying amounts of residual bGC activity which may be sufficient to prevent GlcCer accumulation to levels at which more significant Gaucher-like pathologies might be seen. Despite the absence of robust Gaucher-like phenotypes in LIMP-2 KO mice, it is nonetheless interesting to speculate that some of the diversity in Gaucher phenotypes observed in humans carrying identical bGC mutations might result from secondary mutations in the LIMP-2 pathway.
We observed that, in contrast to the more common bGC disease-related mutant L444P which, like the N370S and G202R mutants, still bound to the LIMP-2 lumenal domain, the bGC mutant P415R could not be transported to lysosomes after coexpression with LIMP-2, suggesting that this mutation directly or indirectly affects the binding site for LIMP-2. Structural analyses of the LIMP-2/bGC complex will be required to evaluate the importance of this bGC region for LIMP-2 binding.
In conclusion, we have identified a function for LIMP-2 as a Man-6-P-independent trafficking receptor for bGC. The discovery of this function helps link together many of the details from previous studies of both LIMP-2 and bGC biology and, importantly, helps clarify the role proposed for LIMP-2 in the biogenesis and maintenance of lysosomes. The nature of how the interaction between these two proteins is mediated, whether there are additional cargoes for LIMP-2, and how this finding plays into the realm of LIMP-2-and bGC-related pathologies will be exciting subjects for future studies.
EXPERIMENTAL PROCEDURES Cell Lines and Mice
Mouse embryonic fibroblasts from LIMP-2-deficient and wild-type mice generated from E12.5 embryos and primary cell lines between passages 3 and 6 were used for the experiments. For rescue experiments, cells were transiently transfected using Fugene 6 (Roche, Mannheim, Germany). Primary macrophages were isolated from mice 4 days after peritoneal injection of 4% thioglycolate (Huynh et al., 2007) . Wild-type and LIMP-2-deficient mice (Gamp et al., 2003) were maintained in a conventional animal facility. All experiments were performed with approval of the National Animal Care Committee of Germany.
Plasmids, Expression, and Purification of Recombinant Proteins Expression plasmids for LIMP-2, bGC, and CD36 were generated as described in Supplemental Data. For protein expression in the BEV system, Tn-5 cells (Expression Systems, Woodland, CA, USA) were infected with recombinant virus at a multiplicity of infection (MOI) = 1. Conditioned medium was harvested 48 hr postinfection by centrifugation at 500 3 g and 0.22 mm filtered. Proteins expressed as fusions to the 12 amino acid HPC4 epitope tag were purified from the medium as described by Rezaie et al. (1992) . Recombinant human bGC was purified as we previously described (Sawkar et al., 2006) .
Affinity Chromatography and Binding Assays
Purified recombinant bGC was covalently coupled to CNBr-activated Sepharose 4B (Sigma Chemical, St. Louis, MO, USA) as described by Reczek et al. (1997) or coupled using the AminoLink immobilization kit (Pierce, Rockford, IL, USA). Mouse tissue extracts were prepared from frozen tissues (Pel-Freeze Biologicals, Rogers, AR, USA) and small-scale affinity-chromatography experiments performed essentially as described (Reczek et al., 1997) . For large-scale affinity chromatography, bound proteins were eluted from the coupled resin in 50 mM sodium acetate (pH 4.7), 1 M sodium chloride. Antibody-based pull-down experiments were done using a monoclonal antibody to the HPC4 epitope covalently coupled to NHS-activated Sepharose 4 Fast Flow resin (AP-Biotech, Little Chalfont Buckinghamshire, UK). Resin was incubated with solutions of HPC4 epitope-tagged proteins, or non-epitope-tagged proteins as controls, or with a mixture of epitope-tagged protein and proteins to be tested for binding by cocapture in buffers containing 1 mM calcium chloride to allow for the calciumdependent HPC4 epitope-antibody interaction. Five to ten micrograms of each protein was used per reaction. Following extensive washing in the presence of 1 mM calcium chloride, HPC4-tagged and cocaptured proteins were eluted in buffer containing 5 mM EDTA in place of calcium chloride and the sample was analyzed by SDS-PAGE.
Enzyme Activity Assays, PNGase-F, EndoH Treatment, and GL1-Substrate Analysis The 4MU-based activity or colorimetric assay for bGC and a-galactosidase and the quantitation of tissue glucosylceramide levels were performed using methods described previously (Marshall et al., 2002) . PNGase-F and EndoH treatment of LIMP-2 or bGC were performed using kits from New England Biolabs (Beverly, MA, USA) and Roche, respectively. Immunostaining, Immunoprecipitations, Pulse-Chase Analysis, and Antibodies The procedures for immunoblotting, coimmunoprecipitation, and immunostaining of cells grown on coverslips and tissue sections, pulse-chase analysis in HeLa cells, and all antibodies used in this study are described in Supplemental Data.
LIMP-2 siRNA
Northern Blotting
Total RNA of kidney, liver, and fibroblasts were prepared using RNAeasy columns from QIAGEN (Hilden, Germany). Total RNA samples were separated on an agarose gel and blotted on nylon filters. Filters were hybridized overnight with a mouse bGC or mouse glyceraldehyde dehydrogenase cDNA probe, washed, exposed to an imaging plate, and developed with the Fuji FLA-5000 phosphoimager (Fujifilm, Tokyo, Japan).
Mass Spectroscopy LIMP-2 affinity purified from murine liver extract was resolved by SDS-PAGE, stained with Coomassie brilliant blue R-250, excised from the gel, and in-gel digested with trypsin, and the resulting peptides were analyzed by nano-LC/MS/MS to obtain peptide sequence data. These data were used to query the National Center for Biotechnology The preferential binding of bGC to LIMP-2 (binding complex is highlighted in inset) at more neutral pH suggests these two proteins associate in secretory compartments as early as the ER or Golgi apparatus, from where they then progress to distal, more acidic prelysosomal compartments (LE, late endosomes) and eventually to dense lysosomes (LYSO).
At the lower pH of these compartments, bGC may dissociate from LIMP-2. Yellow arrows, LIMP-2 pathway. The M6P-receptor pathway (white arrows) is shown for comparison.
Information (Bethesda, MD, USA) nonredundant database using the Mascot program (Matrix Science, Boston, MA, USA).
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures and nine figures and can be found with this article online at http:// www.cell.com/cgi/content/full/131/4/770/DC1/.
